Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J eliminates more R&D jobs...

July 3, 2006 | A version of this story appeared in Volume 84, Issue 27

Johnson & Johnson is consolidating its West Coast pharmaceutical operations as part of an overall realignment of its drug business. The Fremont, Calif., research facility of J&J's biopharma subsidiary Scios will be closed. R&D programs will be shifted to J&J's Pharmaceutical Research & Development site in La Jolla, Calif., and to the Mountain View, Calif., campus of another J&J subsidiary, Alza. The moves will result in the loss of about 500 jobs across Scios and Alza. Earlier this year, J&J said it would close its Raritan, N.J., drug discovery unit, shedding 280 positions at the site (C&EN, Feb. 27, page 6).

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.